Aaron Levitt

InvestorPlace Contributor

Aaron Levitt is an independent investment analyst and author living in State College, Pennsylvania. His work appears in several high profile publications in both print and on the web.

As an advocate for long-term globally oriented investing, Aaron believes that exchange traded funds have leveled playing field for Main Street. Following global macro-economic trends, investors now have several avenues to create great long term portfolios.

Aaron is a graduate of The Pennsylvania State University where he studied Economics and International Business. Aside for helping regular investors develop winning portfolios, his current projects include writing his first book on alternative energy investing.

Follow his picks and pans on Twitter at @AaronLevitt.

Recent Articles

Bristol-Myers Becomes a Cancer-Fighting Giant With Celgene Buyout

By Aaron Levitt, InvestorPlace Contributor Jan 4, 2019

With its Celgene (CELG) buyout, Bristol-Meyers is getting a heck of a deal and will make BMY stock the top-dog cancer medicines.

After a Terrible Run, KMI Stock Is Too Cheap to Pass Up

By Aaron Levitt, InvestorPlace Contributor Jan 3, 2019

After its latest dip, Kinder Morgan is looking pretty cheap. Perhaps even better when you consider the outlook for KMI stock.

5 ETFs to Lower Your Taxes

By Aaron Levitt, InvestorPlace Contributor Dec 18, 2018

Want to avoid Uncle Sam's fingers in your wallet? Then turn towards ETFs for your portfolio. Here are five ETFs that can help fight taxes.

5 Exotic ETFs to Buy for a Better Portfolio in 2019

By Aaron Levitt, InvestorPlace Contributor Dec 14, 2018

A dose of out of box ETFs could do your portfolio good next year. Here are five great choices to build a better portfolio.

Buying Tesla Stock Is a Terrible Investment in a Spectacular Product

By Aaron Levitt, InvestorPlace Contributor Dec 13, 2018

A lawsuit, a new strange interview and continued tweeting. Just what the heck is going on at Tesla and how is it going to effect TSLA stock?